AbbVie Inc. (ABBV) research: valuation against peers, fundamentals over time, risk and news coverage
ABBV
AbbVie Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYNEUTRALQ2 Earnings Season Breaks Its Own Rules as Share-Price Reactions Decouple From Results
Analysts flag a widening disconnect between reported fundamentals and share-price reactions during a historic Q2 earnings season, complicating event-driven positioning. AbbVie's guidance for $12.7 billion in neuroscience sales this year is a case study in fundamentals the market has been slow to price.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.
Only 2 resolved forecasts on record — below the 6-period threshold, so no verdict is published.
n = 2 resolved forecasts · FY 2024 to FY 2025 · 1 still outstanding
Insufficient sample — no verdict published. ABBV has 2 resolved forecasts on record, below the 6 needed before we will characterise a management team’s forecasting. The record below is published in full; the company is excluded from every ranking on this site until it clears the threshold.
Next report expected 30 Oct 2026 (Q3 FY2026) — Estimated from the issuer's own filing history: FY2025Q3 results were released on 2025-10-31. source
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2026revised | EPS (adj.) | $13.87–$14.07 | 2026-07-31 | — | — | — | PENDING | guidance |
| “AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the midpoint.” | ||||||||
| FY 2026revised | EPS (adj.) | $14.08–$14.28 | 2026-04-29 | — | — | — | PENDING | guidance |
| “AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.96 - $14.16 to $14.08 - $14.28, which includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2026.” | ||||||||
| FY 2026 | EPS (adj.) | $14.37–$14.57 | 2026-02-04 | — | — | — | PENDING | guidance |
| “AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2026 of $14.37 to $14.57.” | ||||||||
| FY 2025revised | EPS (adj.) | $10.61–$10.65 | 2025-10-31 | $10.00 | −5.7% | BELOW | guidance · result | |
| “AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2025.” | ||||||||
| FY 2025revised | EPS (adj.) | $11.88–$12.08 | 2025-07-31 | $10.00 | −15.7% | BELOW | guidance · result | |
| “AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.67 - $11.87 to $11.88 - $12.08, which includes an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2025.” | ||||||||
| FY 2025revised | EPS (adj.) | $12.09–$12.29 | 2025-04-25 | $10.00 | −17.1% | BELOW | guidance · result | |
| “Raises 2025 Adjusted Diluted EPS Guidance Range from $11.99 - $12.19 to $12.09 - $12.29, which Includes an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the First Quarter 2025” | ||||||||
| FY 2025 | EPS (adj.) | $12.12–$12.32 | 2025-01-31 | $10.00 | −17.3% | BELOW | guidance · result | |
| “AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2025 of $12.12 to $12.32.” | ||||||||
| FY 2024revised | EPS (adj.) | $10.90–$10.94 | 2024-10-30 | $10.12 | −7.1% | BELOW | guidance · result | |
| “Raises 2024 Adjusted Diluted EPS Guidance Range from $10.67 - $10.87 to $10.90 - $10.94, which Includes an Unfavorable Impact of $0.64 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2024” | ||||||||
| FY 2024 | EPS (adj.) | $10.71–$10.91 | 2024-07-25 | $10.12 | −5.5% | BELOW | guidance · result | |
| “AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 - $10.81 to $10.71 - $10.91, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024.” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.